| 101 |
35463360 | Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance. | 2022 |
2 |
| 102 |
35467492 | Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S. | 2022 Apr 25 |
3 |
| 103 |
35468939 | CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression. | 2022 May |
2 |
| 104 |
35473448 | Factors affecting outcome in resected EGFR-mutated lung cancer. | 2022 Jun |
1 |
| 105 |
35479327 | Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report. | 2022 |
1 |
| 106 |
35489768 | Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer. | 2022 May |
3 |
| 107 |
35494030 | Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review. | 2022 |
2 |
| 108 |
35494059 | Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review. | 2022 |
7 |
| 109 |
35499406 | HJM-561, a potent, selective and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations. | 2022 May 2 |
3 |
| 110 |
35506019 | Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib. | 2022 |
2 |
| 111 |
35511414 | Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer. | 2022 May |
1 |
| 112 |
35527328 | Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR). | 2022 May 9 |
1 |
| 113 |
35529794 | Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report. | 2022 Apr |
1 |
| 114 |
35530305 | Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib. | 2022 |
6 |
| 115 |
35530643 | Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer. | 2022 May-Jun |
2 |
| 116 |
35534623 | Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. | 2022 May 9 |
1 |
| 117 |
35551303 | Non-small cell lung carcinoma spheroid models in agarose microwells for drug response studies. | 2022 Jun 14 |
2 |
| 118 |
35571073 | Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series. | 2022 |
3 |
| 119 |
35572898 | Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). | 2022 Apr |
1 |
| 120 |
35574304 | Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report. | 2022 |
1 |
| 121 |
35596880 | Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer. | 2022 Jun |
2 |
| 122 |
35621675 | Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation-Case Report and a Literature Review. | 2022 May 13 |
2 |
| 123 |
35626421 | Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report. | 2022 May 19 |
1 |
| 124 |
35633141 | Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients. | 2022 May 28 |
3 |
| 125 |
31802642 | When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival. | 2021 Apr |
1 |
| 126 |
31935159 | Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data. | 2021 Jun |
3 |
| 127 |
32276580 | BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC). | 2021 May |
3 |
| 128 |
32398685 | Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. | 2021 Jan |
4 |
| 129 |
32467321 | Reduced sensitivity for EGFR T790M mutations using the Idylla EGFR Mutation Test. | 2021 Jan |
3 |
| 130 |
32498573 | Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia. | 2021 Aug |
2 |
| 131 |
32541922 | MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer. | 2021 Jan |
1 |
| 132 |
32556898 | Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. | 2021 Feb |
1 |
| 133 |
32641247 | Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator). | 2021 May |
9 |
| 134 |
32678313 | TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance. | 2021 Mar |
2 |
| 135 |
32839131 | Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report. | 2021 Jul |
1 |
| 136 |
32955628 | Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. | 2021 Apr |
5 |
| 137 |
32972042 | A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1. | 2021 Jan |
6 |
| 138 |
32999231 | Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer. | 2021 Feb 15 |
3 |
| 139 |
33009209 | Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line. | 2021 Mar 1 |
2 |
| 140 |
33040541 | The combination of camrelizumab and apatinib obtained ongoing partial remission for a patient with osimertinib-resistant non-small cell lung cancer: case report. | 2021 Mar |
1 |
| 141 |
33060857 | The next tier of EGFR resistance mutations in lung cancer. | 2021 Jan |
1 |
| 142 |
33122107 | Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC. | 2021 Feb |
1 |
| 143 |
33129919 | Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity. | 2021 Jan 10 |
1 |
| 144 |
33131198 | Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). | 2021 Jan |
7 |
| 145 |
33132329 | Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review. | 2021 Apr 1 |
3 |
| 146 |
33151783 | Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia. | 2021 Jun |
1 |
| 147 |
33153414 | EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges. | 2021 Oct |
2 |
| 148 |
33199228 | A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). | 2021 Mar |
1 |
| 149 |
33205587 | Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial. | 2021 Jan |
1 |
| 150 |
33219754 | Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. | 2021 Feb |
12 |